Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidenceAngiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
- Other Titles
- Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
- Authors
- Hong-Mi Choi; Mi-Seung Shin
- Issue Date
- May-2020
- Publisher
- 대한내과학회
- Keywords
- Heart failure; Angiotensin receptor inhibitor; Neprilysin
- Citation
- The Korean Journal of Internal Medicine, v.35, no.3, pp.498 - 513
- Journal Title
- The Korean Journal of Internal Medicine
- Volume
- 35
- Number
- 3
- Start Page
- 498
- End Page
- 513
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/45690
- ISSN
- 1226-3303
- Abstract
- Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/45690)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.